Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Enrolling by invitation Not applicable

The Effect of Motivational Interviewing on Knowledge, Self-Efficacy, and Treatment Adherence in Patients With Primary Hypertension Living in Semi-Rural Areas

NCT07307924 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2025-12-30
Last updated
2026-01-02

Condition(s) studied

Healthy Individuals (Controls)PRIMARY HYPERTENSION PATIENT

Investigational drug(s) / intervention(s)

Motivasyonel görüşme

Motivasyonel görüşme: Hipertansiyon hastalarında yaşam tarzı değişikliklerinin teşvik edilmesi, tedaviye uyumun artırılması ve öz yeterlilik düzeylerinin geliştirilmesine yönelik yapılandırılmış müdahale programları, son yıllarda literatürde önemli yer edinmiştir. Sonuç olarak, MG tabanlı müdahaleler süre, içerik ve uygulama araçları bakımından çeşitlilik gösterse de, katılımcıların tedaviye uyumunu ve yaşam tarzı değişikliklerini desteklemek üzere çok yönlü ve yapılandırılmış programlar olarak öne çıkmaktadır. Bu bağlamda, çalışmamızda SİM temelli MG programının maksimum 8 hafta süresince, iki haftada bir olacak şekilde 4 oturumdan oluşacak ve her oturumun 30 ila 45 dakika arasında değişen sürelerde gerçekleştirilmesi planlanmaktadır. Eğitim içeriği, katılımcıların bilişsel düzeyleri, sağlık algıları ve davranış değişimine yönelik motivasyon düzeyleri dikkate alınarak yapılandırılmıştır.

Study summary

This study is a single-center, single-blind, parallel-group randomized controlled trial designed to examine the impact of a Health Belief Model (HBM)-based motivational interviewing (MI) intervention on knowledge level, self-efficacy, and treatment adherence among primary hypertension patients living in a semi-rural region. Hypertension, despite its typically asymptomatic course, is a prevalent chronic condition that contributes significantly to cardiovascular morbidity and mortality. Poor adherence to treatment and insufficient disease-related knowledge remain major barriers to achieving optimal blood pressure control. Self-efficacy is recognized as a crucial psychological determinant influencing lifestyle modification and medication adherence, and theoretical models-particularly the HBM-provide a structured framework for understanding individuals' health perceptions and facilitating behavioral change.

Motivational interviewing, a patient-centered counseling method aimed at strengthening intrinsic motivation, is thought to be particularly effective when combined with the HBM. The integration of these two approaches is expected to enhance individuals' readiness for change and promote active engagement in treatment. Existing evidence indicates that MI-based interventions can improve medication adherence, encourage lifestyle modifications, increase self-efficacy, and support better blood pressure control. These findings form the conceptual basis of the present study.

The trial was conducted between November 2025 and April 2026 at Hisarardı Family Health Center in Simav, Kütahya. The target population consisted of 140 individuals diagnosed with primary hypertension. Using G\*Power with an effect size of 0.60, 80% power, and α=0.05, the required sample size was calculated as 50 participants per arm. Stratified randomization by sex and block randomization with blocks of four were employed.

The intervention group received a four-session MI program structured according to the HBM, consisting of the following components:

Enhancing risk perception and awareness of disease severity Highlighting treatment benefits and reducing perceived barriers Strengthening self-efficacy and developing a personalized action plan Strategies for maintaining behavioral change and identifying cues to action Each session lasted 30-45 minutes and was delivered biweekly. Participants in the control group did not receive any educational intervention and continued with routine clinical follow-up only.

Data were collected using the following instruments:

Hypertension Knowledge Level Scale Hill-Bone Medication Adherence Scale Hypertension Self-Efficacy Scale Systolic and diastolic blood pressure measurements Assessments were conducted at baseline (0 month), mid-intervention (3 months), and at the end of follow-up (6 months). Statistical analyses will be performed using SPSS 26.0, including paired and independent sample tests, correlation analyses, and effect size calculations.

Ethics approval, institutional permissions, and scale-use authorizations were obtained prior to data collection, and all procedures were carried out in accordance with the Declaration of Helsinki.

This study is expected to offer valuable insights into the applicability of theory-driven educational interventions in primary care settings, clarify the contribution of motivational interviewing to hypertension management, and inform national initiatives such as the Disease Management Platform (HYP).

Eligibility

Sex
ALL
Min age
25 Years
Max age
59 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Being diagnosed with primary hypertension, * Being between 25 and 59 years of age, * Having had a confirmed primary hypertension diagnosis for at least 12 months, * Being literate and able to communicate in Turkish, * Voluntarily agreeing to participate in the study. Exclusion Criteria: * Having cognitive impairment, dementia, or a severe psychiatric diagnosis, * Having a diagnosis of secondary hypertension, * Being pregnant or in the breastfeeding period, * Having a physical disability or communication problem that would prevent active participation in the educational sessions.

Primary outcome measure(s)

  • The knowledge levels of individuals in the intervention group demonstrate a significant increase after the training compared with those in the control group. — March 2026 (3 months later)
    The knowledge levels of individuals in the intervention group show a significant increase after the training compared with those in the control group.
  • The knowledge levels of individuals in the intervention group increase significantly after the training compared with those in the control group. — June 2026 (6 months after onset)
    The knowledge levels of individuals in the intervention group show a significantly greater increase after the training compared with those in the control group.

Trial sites (1)

FacilityCityRegionStatus
Hisarardı Family Health Center affiliated with the Simav District Health Directorate Kütahya Kütahya/ Simav

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07307924 on ClinicalTrials.gov ↗ ← All trials in Turkey